.Pharmacolibrary.Drugs.ATC.B.B03XA02_1 .Pharmacolibrary.Drugs.ATC.B.B03XA02_1| name: | DarbepoetinAlfa_1 |
| ATC code: | B03XA02_1 | route: | subcutaneous |
| n-compartments | 2 |
Darbepoetin alfa is a synthetic analog of erythropoietin used to stimulate erythropoiesis. It is approved for the treatment of anemia associated with chronic kidney disease (CKD) and chemotherapy-induced anemia in cancer patients. It is longer-acting than recombinant human erythropoietin due to additional sialic acid groups.
Pharmacokinetic parameters in healthy adult volunteers after subcutaneous administration.
An, G, et al., & Veng-Pedersen, P (2017). Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing. Journal of pharmaceutical sciences 106(6) 1644–1649. DOI:10.1016/j.xphs.2017.02.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28189627
Agoram, B, et al., & Sullivan, JT (2007). Population pharmacokinetics of darbepoetin alfa in healthy subjects. British journal of clinical pharmacology 63(1) 41–52. DOI:10.1111/j.1365-2125.2006.02752.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16939525
Kawakami, K, et al., & Akizawa, T (2009). Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration. European journal of clinical pharmacology 65(2) 169–178. DOI:10.1007/s00228-008-0561-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/18807251